This current toolkit is an updated version of the toolkit on medicines use review (MUR) published in December 2020. In this version, MUR is framed as a subtype of MR, with further distinction made between each type of professional service. In fact, emphasis is made on the conceptual difference between both services, with MR representing a clinical assessment of a patient’s current medicines, and with MUR representing partnerships between pharmacists and patients to improve their medicines use through education, identification, integration of their preferences and optimisation of their medication adherence.
Emerging data show that medication errors and adverse events cause significant harm to patients’ health and well-being. It is estimated that the burden of adverse events due to medicines is now comparable to that of widespread diseases, such as malaria or tuberculosis. 1 The impacts of medication errors also represent a burden for health systems, with the annual cost associated with medication errors estimated at USD 42 billion worldwide.
